The stock is trading near the C$2.41 acquisition price, so the primary catalyst is the Hanmi deal closing. Monitor for Korean regulatory approval updates in the coming weeks. The EHA oral presentation in June could provide a pipeline catalyst if data is strong, but the acquisition overhang dominates near-term price action.
Price Chart
Executive Summary
Aptose reported Q1 2026 results with a net loss of $7.6M, wider than the $5.5M loss in Q1 2025, as R&D spending increased on the TUSCANY trial. The key event is the delayed closing of the Hanmi acquisition (C$2.41/share, 28% premium), now targeted for May 2026, with an oral presentation at EHA 2026 in June. The company has only $4.1M cash and relies on Hanmi advances to fund operations, making the deal's completion critical.
Key Financial Metrics
Key Facts
- Net loss for Q1 2026 was $7.6M, up from $5.5M in Q1 2025, driven by increased TUSCANY trial costs
- Cash and restricted cash at March 31, 2026 was $4.1M, essentially flat from $4.1M at year-end 2025
- Working capital deficit worsened to ($5.1M) from ($2.9M) at December 31, 2025
- Hanmi acquisition delayed; closing targeted for May 2026 pending Korean regulatory approvals
- Shareholders to receive C$2.41/share, a 28% premium over 30-day VWAP of C$1.88
- TUS+VEN+AZA triplet data selected for oral presentation at EHA 2026 Congress (June 11-14)
- Luxeptinib license rights returned to CGI; trial being wound down
- Company does not have sufficient cash to fund operations and relies on Hanmi advances
Financial Impact
Net loss increased $2.1M YoY to $7.6M; cash runway dependent on Hanmi acquisition closing
Risk Factors
- Hanmi acquisition fails to close, leaving Aptose with insufficient cash to fund operations
- Further delays in Korean regulatory approvals could extend uncertainty
- Widening net losses and negative working capital indicate financial distress without the deal
- Dilution risk from 1.1M outstanding warrants if exercised
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003381 |
| Document: f8k_051326.htm | 0001171843-26-003381 |
| Document: 0001171843-26-003381-index-headers.html | 0001171843-26-003381 |
| Document: 0001171843-26-003381-index.html | 0001171843-26-003381 |
| Document: 0001171843-26-003381.txt | 0001171843-26-003381 |
| 8-K Data (Synthetic) | 0001171843-26-003381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 1, 2026 16w ago | 15-12G | $1.68 $1.69 | ▼ −0.60% | ▼ −0.64% | — |
Jun 15, 2026 19w ago | 8-K | $1.61 $1.48 | ▼ −8.07% | ▼ −5.46% | — |
May 29, 2026 21w ago | 8-K | $1.65 $1.57 | ▼ −4.85% | ▼ −2.32% | — |
May 13, 2026 23w ago | 8-K | $1.71 $1.71 | · 0.00% | ▲ +0.72% | — |
Mar 19, 2026 31w ago | 8-K | $1.62 $1.64 | ▲ +1.23% | ▲ +3.45% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers